Blood test and genetic data predict Alzheimer's deterioration timing
A study in The Lancet Neurology reveals that blood values and genetics can predict the timeline of cognitive decline.
A comprehensive study published in The Lancet Neurology showed that combining blood levels of p-tau217 and APOE genetics can play a significant role in predicting the timing of cognitive decline associated with Alzheimer's disease.
Scope of the Research
These important results were achieved by combining data from seven major studies involving a total of 8,582 individuals from different ethnic backgrounds.
Key Indicators Examined
The two main biological indicators examined during the research process were blood p-tau217 levels and individuals' APOE genotype.
Genetics and Blood Markers
While the p-tau217 protein shows a close relationship with amyloid and tau pathology in the brain, the APOE4 variant stands out among genetic risk factors.
Timing of Deterioration
While the window for symptom onset drops to an average of 3 to 4 years in APOE4 carriers, this period extends to 5 to 6 years in other APOE types.
Experts' Evaluations
Experts emphasize that these tests are not definitive prophecies, but rather probabilistic estimates derived from large populations.